Spravato treatment available
Silver Spring
Maryland
Spravato® esketamine treatment
When depression has not improved enough with previous treatment, Spravato may be an option worth discussing with a psychiatric provider.
Blue Sky provides supervised Spravato treatment at its Silver Spring, MD; Laurel, MD; and Washington, DC locations. All three offices are certified under the SPRAVATO REMS program.
A psychiatric evaluation is required to determine whether Spravato is appropriate for you.
Medically reviewed by Jason Eliassaint, PMHNP-BC
Psychiatric/Mental Health Nurse Practitioner · Owner
Blue Sky Mental Health Clinic
Last reviewed:
In brief
Sources: FDA drug record and prescribing information · SPRAVATO REMS
When depression hasn’t improved enough
Some people continue experiencing significant depression symptoms even after trying previous treatments. Spravato is a prescription esketamine nasal spray approved for certain adults with treatment-resistant depression.
Current FDA labeling allows use either alone or with an oral antidepressant for treatment-resistant depression. An evaluation helps a provider understand your treatment history and whether this approach might fit your care plan.
Understanding the treatment
Spravato is the brand name for esketamine nasal spray. Esketamine is related to ketamine, but Spravato is a distinct FDA-approved medication with its own administration and safety requirements.
FDA materials identify risks including sedation, dissociation, respiratory depression, and abuse or misuse. Because of these risks, it is available through the restricted SPRAVATO REMS program and must be administered under supervision in a certified healthcare setting.
Individual assessment
It may be considered for some adults whose depression has not responded adequately to previous treatment. Not everyone will be a candidate.
A provider may review:
The purpose of an evaluation is to determine which approach makes sense for you, not to automatically prescribe Spravato.
What to expect
A provider reviews your symptoms, prior treatment, medications, medical history, and relevant safety considerations.
If Spravato is appropriate, your care team explains the treatment schedule, preparation, monitoring, and alternatives.
Spravato is administered as a nasal spray under healthcare supervision at a certified healthcare setting. It is not taken home.
Patients are monitored for at least two hours after each treatment session.
A provider assesses response and tolerability over time and considers whether the care plan needs to change.
Evaluation coordination
Blue Sky provides Spravato treatment at all three locations, each certified under the SPRAVATO REMS program. Choose your preferred office when requesting an evaluation; a psychiatric provider will determine whether treatment is appropriate for you.
Spravato treatment available
Maryland
Spravato treatment available
Maryland
Spravato treatment available
District of Columbia
Safety & supervision
Spravato has important safety considerations. FDA labeling and REMS requirements describe risks including sedation, dissociation, respiratory depression, and abuse or misuse. This is why administration and observation happen in a certified healthcare setting.
No. Spravato contains esketamine, which is related to ketamine, but it is a distinct FDA-approved nasal spray with specific approved uses and REMS requirements. Ketamine itself is not FDA-approved to treat psychiatric disorders.
Why Blue Sky
Treatment-resistant depression is rarely just about choosing one medication. Blue Sky also provides psychiatric care that can help inform a broader treatment plan.
A clinical evaluation considers the larger picture before any treatment decision.
Practical questions
Coverage varies by insurance plan and may involve authorization requirements. Contact Blue Sky to discuss the next steps for reviewing your particular benefits. Coverage and eligibility are not guaranteed.
Good questions to ask
For more background, read our patient guide to Spravato and esketamine.
Yes. Spravato is FDA-approved for treatment-resistant depression in adults. Current labeling permits its use alone or with an oral antidepressant. A separate indication involving acute suicidal ideation or behavior specifies use with an oral antidepressant.
No. Spravato contains esketamine, which is related to ketamine, but it is a distinct FDA-approved nasal spray with specific administration and safety requirements.
No. Spravato must be administered under supervision in a certified healthcare setting through the SPRAVATO REMS program.
Patients are monitored for at least two hours following administration. Your care team will explain the monitoring requirements if treatment is appropriate for you.
Yes. Blue Sky provides Spravato treatment at its Silver Spring location. A psychiatric evaluation is required to determine whether it may be appropriate for you.
Yes. Blue Sky provides Spravato treatment at its Laurel location. A psychiatric evaluation is required to determine whether it may be appropriate for you.
Yes. Blue Sky provides Spravato treatment at its Washington, DC location. A psychiatric evaluation is required to determine whether it may be appropriate for you.
Coverage depends on your individual plan and any authorization requirements. Contact Blue Sky to discuss what information may be needed to review your benefits.
Start with a psychiatric evaluation. A provider reviews your symptoms, previous treatment, medications, medical history, and other factors before discussing whether Spravato may be appropriate.
The next conversation
If depression has not improved enough with previous treatment, Blue Sky Mental Health Clinic can evaluate whether Spravato may be one appropriate next step.
A considered next step
Tell us how to reach you. Our team can follow up about an evaluation and discuss practical next steps. Submitting this form does not establish eligibility or guarantee treatment.